Skip to main content
Midas Edge

GUIDED THERAPEUTICS INC

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

GTHPStored price and day change unavailable
See the whole filing, with its images and exhibits
Contents

Item 1. Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
June 30,December 31,
20242023
ASSETS
Current Assets:
Cash and cash equivalents$275$591
Trade receivables, net of allowance for doubtful accounts of nil and $2 at June 30, 2024 and December 31, 2023, respectively.27
Inventory, net of reserves of $818 at June 30, 2024 and December 31, 2023632632
Other current assets112163
Total current assets1,0211,393
Non-Current Assets:
Property and equipment, net2832
Operating lease right-of-use assets, net of amortization185227
Other assets1717
Total non-current assets230276
TOTAL ASSETS$1,251$1,669
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable$2,143$1,991
Accounts payable, related parties3432
Accrued liabilities8401,068
Deferred revenue748424
Current portion of lease liability9991
Current portion of long-term debt, related parties52039
Short-term notes payable11259
Short-term convertible debt941,105
Short-term convertible debt in default1,130-
Derivative liability at fair value12-
Total current liabilities5,7324,809
Long-Term Liabilities
Long-term lease liability104155
Long-term notes payable59-
Long-term debt, related parties23511
Total long-term liabilities186666
Total liabilities5,9185,475
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS’ DEFICIT:
Series C convertible preferred stock, $0.001 par value; 9.0 shares authorized, 0.3 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $286 at June 30, 2024 and December 31, 2023.105105
Series C1 convertible preferred stock, $0.001 par value; 20.3 shares authorized, 1.0 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $1,049 at June 30, 2024 and December 31, 2023.170170
Series C2 convertible preferred stock, $0.001 par value; 5,000 shares authorized, 2.7 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $2,700 at June 30, 2024 and December 31, 2023.439439
Series D convertible preferred stock, $0.001 par value; 6.0 shares authorized, 0.4 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $438 at June 30, 2024 and December 31, 2023.159159
Series E convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.9 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $883 at June 30, 2024 and December 31, 2023.834834
Series F convertible preferred stock, $0.001 par value; 1.5 shares authorized, 1.1 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $1,006 at June 30, 2024 and December 31, 2023.838838
Series F-2 convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.5 shares issued and outstanding as of June 30, 2024 and December 31, 2023. Liquidation preference of $520 at June 30, 2024 and December 31, 2023.475475
Common stock, $0.001 par value; 500,000 shares authorized, 56,267 and 54,105 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively.3,4423,441
Additional paid-in capital141,320140,983
Treasury stock at cost(132)(132)
Accumulated deficit(152,317)(151,118)
Total stockholders’ deficit(4,667)(3,806)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT$1,251$1,669

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.